Fred R Hirsch, MD, PhD

About Me

Fred R. Hirsch, MD, PhD, FASCO is the Ning Zhao Chair and Professor of Medicine (Hematology and Medical Oncology) and Pathology and Executive Director of the Center for Thoracic Oncology at the Icahn School of Medicine at Mount Sinai. He is also Co-Director of the Center of Excellence for Thoracic Oncology and Associate Director of Biomarker Discovery at the Mount Sinai Tisch Cancer Center, a NCI-Designated Comprehensive Cancer Center.

Before joining Mount Sinai, Dr. Hirsch was Professor of Medicine and Pathology at the University of Colorado for 18 years and Chief Executive Officer of the International Association for the Study of Lung Cancer (IASLC) for five years.

Dr. Hirsch has received numerous awards and honors, including the IASLC Mary Matthews Award for Translational Research in Lung Cancer in 2007, the Japanese Lung Cancer Society Merit Award in 2010, the Addario Foundation Lecture Award in 2015, the Wuan Ki Hong Lectureship Award in 2019, and the Heine H. Hansen Award from the European Society of Medical Oncology (ESMO)/ IASLC in 2022.

Dr. Hirsch has contributed to more than 500 publications in peer-reviewed journals. He is an internationally renowned authority on lung cancer treatment and research.

Dr. Hirsch is on X at @Fred_Hirsch

Research Focus

Dr. Hirsch’s career in lung cancer research spans more than 25 years and includes translational research, targeted therapies, and early detection of lung cancer. His research has helped identify and validate prognostic markers for lung cancer outcomes and biomarkers for personalized lung cancer therapies that illustrate how these therapies work and who is most likely to benefit from them.

Language

English

Position

PROFESSOR | Medicine, Hematology and Medical Oncology, PROFESSOR | Pathology, Molecular and Cell Based Medicine

Education

MD, University of Copenhagen

PhD, University of Copenhagen

BA, University of Copenhagen Business School

Research

Research Focus Dr. Hirsch’s career in lung cancer research spans more than 25 years and includes translational research, targeted therapies, and early detection of lung cancer. His research has helped identify and validate prognostic markers for lung cancer outcomes and biomarkers for personalized lung cancer therapies that illustrate how these therapies work and who is most likely to benefit from them.